Unraveling galectin-1 as a novel therapeutic target for cancer.

Détails

ID Serval
serval:BIB_DDBB4016EAB3
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Unraveling galectin-1 as a novel therapeutic target for cancer.
Périodique
Cancer Treatment Reviews
Auteur(s)
Astorgues-Xerri L., Riveiro M.E., Tijeras-Raballand A., Serova M., Neuzillet C., Albert S., Raymond E., Faivre S.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
40
Numéro
2
Pages
307-319
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review Publication Status: ppublish
Résumé
Galectins belong to a family of carbohydrate-binding proteins with an affinity for β-galactosides. Galectin-1 is differentially expressed by various normal and pathologic tissues and displays a wide range of biological activities. In oncology, galectin-1 plays a pivotal role in tumor growth and in the multistep process of invasion, angiogenesis, and metastasis. Evidence indicates that galectin-1 exerts a variety of functions at different steps of tumor progression. Moreover, it has been demonstrated that galectin-1 cellular localization and galectin-1 binding partners depend on tumor localization and stage. Recently, galectin-1 overexpression has been extensively documented in several tumor types and/or in the stroma of cancer cells. Its expression is thought to reflect tumor aggressiveness in several tumor types. Galectin-1 has been identified as a promising drug target using synthetic and natural inhibitors. Preclinical data suggest that galectin-1 inhibition may lead to direct antiproliferative effects in cancer cells as well as antiangiogenic effects in tumors. We provide an up-to-date overview of available data on the role of galectin-1 in different molecular and biochemical pathways involved in human malignancies. One of the major challenges faced in targeting galectin-1 is the translation of current knowledge into the design and development of effective galectin-1 inhibitors in cancer therapy.
Mots-clé
Angiogenesis Inhibitors/pharmacology, Animals, Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Calixarenes/pharmacology, Galectin 1/antagonists & inhibitors, Galectin 1/metabolism, Gene Expression Regulation, Neoplastic/drug effects, Humans, Neoplasm Invasiveness/prevention & control, Neoplasms/drug therapy, Neoplasms/metabolism, Neovascularization, Pathologic/drug therapy, Neovascularization, Pathologic/prevention & control, Peptides/pharmacology, Signal Transduction/drug effects, Thiogalactosides/pharmacology, Up-Regulation
Pubmed
Création de la notice
11/02/2015 13:13
Dernière modification de la notice
20/08/2019 17:02
Données d'usage